Ryaltris is a metered, fixed-dose nasal spray that delivers 665mcg of olopatadine hydrochloride and 25mcg of mometasone furoate in each spray.

The FDA has approved the prescription to OTC switch for Perrigo’s Nasonex® 24hr Allergy (mometasone furoate monohydrate 50mcg).

Mometasone furoate nasal spray reduces nighttime and early morning nasal congestion in patients with seasonal allergic rhinitis.

The FDA approved olopatadine hydrochloride and mometasone furoate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and ...

Perrigo announced that the FDA has approved mometasone furoate monohydrate, an intranasal corticosteroid nasal spray designed to treat and prevent hay fever and allergy symptoms, for over-the ...

The US Food and Drug Administration (FDA) has approved a prescription nasal spray for seasonal allergic rhinitis. Mometasone furoate monohydrate (Ryaltris) is approved for adults and pediatric ...